---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-014184"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T06:08:03.150493+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NeuroBo completes Phase 2a MASH trial dosing; topline data due December 2024

## Summary
- Last patient last visit in two-part Phase 2a trial of DA-1241, a GPR119 agonist for MASH.
- 95 of 109 randomized patients completed dosing across Part 1 (DA-1241 vs placebo) and Part 2 (DA-1241 + sitagliptin vs placebo).
- Primary endpoint: change from baseline in ALT at Week 16; secondary endpoints include lipid and safety measures.
- Topline data from both parts expected in December 2024; prior Phase 1 showed DA-1241 well tolerated.

## SEC filing metadata
- accession: 0001558370-24-014184
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837024014184/0001558370-24-014184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837024014184/nrbo-20241104x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-014184
- JSON: https://secwatch.observer/filing/0001558370-24-014184.json
- Plain text: https://secwatch.observer/filing/0001558370-24-014184.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.